Chensi Biotechnology (Kunming) Co., Ltd. unveiled its group strategic layout covering Kunming, Shanghai and Hangzhou, forming a complete industrial chain for pathology R&D, manufacturing, sales and technical services.
Kunming headquarters takes charge of international sales and Southwest China market operation. Its branch EzoneBio (Shanghai) focuses on pathology equipment R&D and mass production, developing microtomes, laser markers, flotation baths and slide baking instruments. Ailian Bio (Hangzhou) specializes in preclinical pathology CRO testing, equipped with full Leica pathological devices and senior pathologist teams for strict quality control.
The three locations share complementary advantages: Shanghai handles equipment development and production adaptation, Hangzhou delivers pathological technical verification, and Kunming integrates global supply chains and overseas market expansion.
Relying on cross-regional technical collaboration, Chensi Bio identifies actual pain points in lab operations and converts practical demands into cost-effective, user-friendly pathology products. At present, its products cover over 30 domestic provinces, with core overseas markets in Southeast Asia, Europe and North America.